Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $23.71 Average Target Price from Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given a consensus recommendation of “Moderate Buy” by the nine analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $23.7143.

ZVRA has been the topic of several recent research reports. Wall Street Zen cut Zevra Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 20th. JMP Securities dropped their target price on Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 13th. HC Wainwright initiated coverage on Zevra Therapeutics in a research report on Wednesday, July 2nd. They set a “buy” rating and a $26.00 target price on the stock. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Finally, Cantor Fitzgerald raised their price objective on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Thursday, July 10th.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director John B. Bode purchased 5,000 shares of the stock in a transaction on Tuesday, August 19th. The stock was bought at an average price of $9.16 per share, with a total value of $45,800.00. Following the transaction, the director owned 45,000 shares in the company, valued at $412,200. The trade was a 12.50% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.40% of the stock is owned by insiders.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. increased its stake in shares of Zevra Therapeutics by 30.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after purchasing an additional 1,280 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Zevra Therapeutics in the 4th quarter valued at about $53,000. GAMMA Investing LLC increased its stake in shares of Zevra Therapeutics by 20,564.1% in the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock valued at $60,000 after purchasing an additional 8,020 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares in the last quarter. Finally, Creative Planning purchased a new position in shares of Zevra Therapeutics in the 2nd quarter valued at about $92,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Trading Up 0.2%

ZVRA opened at $8.95 on Wednesday. The stock’s fifty day moving average is $10.57 and its two-hundred day moving average is $8.89. The company has a market capitalization of $502.36 million, a P/E ratio of -42.62 and a beta of 1.56. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.